Supernus Pharmaceuticals (SUPN) Long-Term Investments (2012 - 2024)
Supernus Pharmaceuticals (SUPN) posted quarterly Long-Term Investments of $11.7 million for Q1 2024, down 78.47% year-over-year from $54.2 million in Q2 2023, and down 29.82% on a QoQ basis from $16.6 million in Q4 2023.
Supernus Pharmaceuticals (SUPN) Long-Term Investments (2012 - 2024) Analysis & Trends
Supernus Pharmaceuticals has reported Long-Term Investments for 13 years, with the latest figure at $11.7 million in Q1 2024.
- Long-Term Investments for Q1 2024 came in at $11.7 million, down 78.47% year-over-year; the trailing twelve-month figure through Mar 2024 was $11.7 million (down 78.47% YoY), and the FY2023 annual result was $16.6 million, down 82.3% from the prior year.
- Long-Term Investments declined to $11.7 million in Q1 2024, from $16.6 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $534.7 million in Q1 2020 and troughed at $11.7 million in Q1 2024.
- A 5-year average of $206.5 million and a median of $128.6 million in 2022 frame the typical range for Long-Term Investments.
- The widest annual swing landed in 2021, when Long-Term Investments increased 4.46%; it then tumbled 82.3% in 2023.
- A 5-year view of Long-Term Investments shows it stood at $350.4 million in 2020, then plunged by 65.99% to $119.2 million in 2021, then fell by 21.21% to $93.9 million in 2022, then tumbled by 82.3% to $16.6 million in 2023, then slipped by 29.82% to $11.7 million in 2024.
- Per Business Quant data, the three most recent Long-Term Investments figures were $11.7 million in Q1 2024, $16.6 million in Q4 2023, and $25.1 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 92.58 Mn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 63.23 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 1.14 Bn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 149.10 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 60.00 Mn |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.37 Bn | 185.39 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 11.66 Mn |
| Dec 31, 2023 | 16.62 Mn |
| Sep 30, 2023 | 25.13 Mn |
| Jun 30, 2023 | 37.48 Mn |
| Mar 31, 2023 | 54.16 Mn |
| Dec 31, 2022 | 93.90 Mn |
| Sep 30, 2022 | 131.94 Mn |
| Jun 30, 2022 | 147.37 Mn |
| Mar 31, 2022 | 125.34 Mn |
| Dec 31, 2021 | 119.17 Mn |
| Sep 30, 2021 | 405.48 Mn |
| Jun 30, 2021 | 445.47 Mn |
| Mar 31, 2021 | 416.57 Mn |
| Dec 31, 2020 | 350.36 Mn |
| Sep 30, 2020 | 388.19 Mn |
| Mar 31, 2020 | 534.71 Mn |
| Dec 31, 2019 | 591.77 Mn |
| Sep 30, 2019 | 596.44 Mn |
| Jun 30, 2019 | 593.75 Mn |
| Mar 31, 2019 | 522.55 Mn |